Xspray Pharma AB

As of June 30, 2026, Xspray Pharma AB carries a market capitalization of 711.25M, placing it among publicly traded companies globally. Its enterprise value stands at 678.64M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Xspray Pharma AB's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Xspray Pharma AB has 47.42M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Xspray Pharma AB maintains a current ratio of 1.39, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Xspray Pharma AB recorded an income tax benefit of -53,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 21, 2026, Xspray Pharma AB's stock has declined approximately 82.08% over the past 52 weeks. The 50-day moving average sits at 18.80, while the 200-day moving average is 46.41.

As of June 30, 2026, Xspray Pharma AB holds 179.91M in cash and equivalents against 147.30M in total debt, resulting in a net debt position of -57.01M. Total book value stands at 637.50M, with working capital of 60.49M providing operational flexibility.

Xspray Pharma AB's most recent stock split took place on April 8, 2026 with a 247:254 split ratio.